OUTCOMES AND HEALTH RESOURCE UTILISATION OF A WEIGHT MANAGEMENT PROGRAMME IN THE UNITED KINGDOM
Author(s)
Saif Al-Chalabi, MBChB, PhD1, Smeeta Sinha, Medicine1, Bilal Alkhaffaf, MBChB, PhD2, Julia Glover-Kirtland, MSc Health Economics and health policy3, Leanne Walsh, BSc(Hons) Biomedical Science-Neuroscience4, Gabrielle Alimorad, BSc, MSc5, Akheel Syed, Medicine6.
1Donal O'Donoghue Renal Research Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK, Manchester, United Kingdom, 2Department of Oesophago-Gastric Surgery, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK, Manchester, United Kingdom, 3Johnson & Johnson Medtech, Berkshire, United Kingdom, 4Health Economics & market access, Johnson & Johnson Medtech, Berkshire, United Kingdom, 5Johnson & Johnson Medtech, Markham, ON, Canada, 6Department of Diabetes, Endocrinology and Obesity Medicine, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK, Manchester, United Kingdom.
1Donal O'Donoghue Renal Research Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK, Manchester, United Kingdom, 2Department of Oesophago-Gastric Surgery, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK, Manchester, United Kingdom, 3Johnson & Johnson Medtech, Berkshire, United Kingdom, 4Health Economics & market access, Johnson & Johnson Medtech, Berkshire, United Kingdom, 5Johnson & Johnson Medtech, Markham, ON, Canada, 6Department of Diabetes, Endocrinology and Obesity Medicine, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK, Manchester, United Kingdom.
OBJECTIVES: Obesity is a global health challenge. Weight management programmes (WMPs) are multidisciplinary strategies aiming to reduce weight and improve health outcomes, but their long-term real-world effectiveness is unclear. This study aimed to descriptively evaluate clinical outcomes and healthcare resource utilisation (HRU) among patients attending a WMP at Salford Care Organisation (SCO), UK.
METHODS: Retrospective study of adults with BMI >30 kg/m² (or >28 kg/m² with hypertension or diabetes) who attended a SCO WMP from 2005-2020. Excluded: bariatric surgery or weight-loss drugs. Outcomes included BMI class changes and weight loss at 5 and 10 years; healthcare resource use (HRU) was mapped to national reference costs. Analyses were descriptive.
RESULTS: From 16,969 enrolled, 390 met inclusion criteria (183 in the overlap cohort). Baseline BMI was 35.6 ± 5.2; 57.4% had hypertension. At 5 years: 62.3% remained in the same BMI class; 21.3% reduced; 16.4% increased. At 10 years: 50.8% remained; 30.6% reduced; 18.6% increased. >10% weight loss was achieved in 3% patients at 5 years and 13% at 10 years. Mean total HRU cost per patient over 10 years was £13,865 (inpatient costs: £7,042).
CONCLUSIONS: WMPs show modest long-term clinical benefits with limited sustained weight loss and substantial HRU, underscoring the need for tailored interventions to achieve meaningful weight loss and improved cost-effectiveness.
METHODS: Retrospective study of adults with BMI >30 kg/m² (or >28 kg/m² with hypertension or diabetes) who attended a SCO WMP from 2005-2020. Excluded: bariatric surgery or weight-loss drugs. Outcomes included BMI class changes and weight loss at 5 and 10 years; healthcare resource use (HRU) was mapped to national reference costs. Analyses were descriptive.
RESULTS: From 16,969 enrolled, 390 met inclusion criteria (183 in the overlap cohort). Baseline BMI was 35.6 ± 5.2; 57.4% had hypertension. At 5 years: 62.3% remained in the same BMI class; 21.3% reduced; 16.4% increased. At 10 years: 50.8% remained; 30.6% reduced; 18.6% increased. >10% weight loss was achieved in 3% patients at 5 years and 13% at 10 years. Mean total HRU cost per patient over 10 years was £13,865 (inpatient costs: £7,042).
CONCLUSIONS: WMPs show modest long-term clinical benefits with limited sustained weight loss and substantial HRU, underscoring the need for tailored interventions to achieve meaningful weight loss and improved cost-effectiveness.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
CO52
Topic
Clinical Outcomes, Economic Evaluation, Epidemiology & Public Health
Topic Subcategory
Clinical Outcomes Assessment
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), No Additional Disease & Conditions/Specialized Treatment Areas